ClinicalTrials.gg
Not yet recruitingNCT07714616LUNAUpdated Oct 23, 2026

Evaluation of the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose Estrogen (LUNA)

A Phase 3 interventional study of Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg in Contraception, sponsored by Eurofarma Laboratorios S.A.. Not yet recruiting at 1 site in Brazil. Open to female participants aged 14 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Prevention

Updated Oct 23, 2026First site in Brazil1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,600
Allocation
Not applicable
Ages
14 Years to 45 Years
Sex
Female
01

Study summary

This study is a Phase III, multicenter, open-label, single-arm clinical trial designed to evaluate the contraceptive efficacy and safety of a new formulation containing N0999 in women of childbearing potential. Approximately 1,600 post-menarche women aged 14 to 45 years who are candidates for systemic hormonal contraception are expected to be enrolled.

All participants will receive the investigational product, consisting of N0999 administered in a 24+4 regimen. Each treatment cycle consists of 24 active tablets followed by 4 inactive tablets. Participants will receive treatment for 13 consecutive 28-day cycles, corresponding to approximately 52 weeks of treatment. Total study participation, including screening and follow-up, is expected to be approximately 58 weeks.

The primary objective of the study is to evaluate contraceptive efficacy over 13 treatment cycles using the Pearl Index in participants aged 35 years or younger. Secondary objectives include assessing the Pearl Index in the overall study population and in participants older than 35 years, evaluating the method-failure Pearl Index based on correct and consistent use, and estimating cumulative pregnancy rates using Life Table Analysis.

Additional objectives include evaluating cycle control, including withdrawal bleeding, intermenstrual spotting, amenorrhea, and bleeding duration, as well as participant satisfaction with study treatment. Exploratory assessments of clinical and laboratory signs of hyperandrogenism will also be performed.

The safety and tolerability of the investigational product will be evaluated throughout the study by monitoring adverse events, serious adverse events, adverse events of special interest, safety-related discontinuations, clinically relevant findings, and laboratory assessments. An Independent Data and Safety Monitoring Committee will oversee participant safety during the trial.

Participants who wish to become pregnant after completing treatment may participate in an additional exploratory follow-up period of up to 12 months to characterize the return of spontaneous menstruation

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

Eurofarma Laboratorios S.A. is the lead sponsor of 64 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to voluntarily participate in the study and provide written (and assent, where applicable) before the performance of any study-specific procedures.
  • Biological female aged 14 to 45 years (inclusive) at the time of informed consent/assent.
  • Post-menarche for at least 1 year.
  • Regular menstrual cycles lasting 21 to 35 days documented during the 3 months prior to screening (for women not using hormonal at screening).
  • Sexually active with a male partner, with a minimum frequency of one vaginal intercourse per month.
  • Male partner who is not known to be subfertile or infertile, has not undergone vasectomy, and is not known to be -positive.
  • Male partner without homosexual intercourse within the previous 5 years without a subsequent negative HIV test and without shared needle use without a subsequent negative HIV test.
  • No history of investigated or diagnosed infertility.
  • Willing to refrain from using another contraceptive method during study treatment.
  • Adequate from previous contraceptive methods:
  • ≥12 months for depot medroxyprogesterone acetate (DMPA, Depo-Provera®);

    1. ≥6 months for monthly combined injectable contraceptives;
    2. ≥3 months for subdermal implants or levonorgestrel-releasing intrauterine systems;
    3. ≥2 spontaneous menstrual cycles for combined oral contraceptives or oral progestogens, or direct switch on the day following the last active tablet, according to the switcher classification.
  • (BMI) ≥16 kg/m².
  • Participants aged 25 years or older must provide documentation of cervical cytology without abnormalities within the previous 18 months or a negative HPV DNA test within the previous 5 years.
  • Participants aged 40 years or older must provide documentation of bilateral mammography without findings suspicious for within the previous 24 months.
  • Willing and able to comply with study requirements, including use of the participant diary and attendance at scheduled visits.
  • Willing to use the product as the primary contraceptive method during the 13 treatment cycles, without routine need for a backup contraceptive method.

Exclusion criteria

Exclusion Criteria:

  • Confirmed or suspected pregnancy, or plans to become pregnant within the next 12 weeks.
  • Childbirth, abortion, or breastfeeding within the previous 3 months.
  • Personal history of cardiovascular disease, including myocardial infarction, stroke, coronary artery disease, peripheral arterial disease, venous thromboembolic disease (deep vein thrombosis or pulmonary embolism), arterial thromboembolic disease, or any condition that increases the risk of these disorders.
  • Known history of cardiomyopathy, heart failure, or cardiac arrhythmia requiring continuous antiarrhythmic therapy.
  • Uncontrolled hypertension (systolic blood pressure >130 mmHg or diastolic blood pressure >80 mmHg) despite antihypertensive treatment, or requiring four or more classes of antihypertensive medications for adequate control.
  • Uncontrolled diabetes mellitus (history of >7.0%) despite treatment with antihyperglycemic medications.
  • Uncontrolled dyslipidemia (history of LDL cholesterol >190 mg/dL and/or triglycerides >500 mg/dL) despite lipid-lowering therapy.
  • Known personal history of thrombophilia.
  • Current smoking of more than 5 cigarettes per day.
  • Any known condition that may worsen with hormonal treatment or interfere with study conduct or interpretation of results, including herpes gestationis, idiopathic jaundice during a previous pregnancy, otosclerosis, Sydenham's chorea, porphyria, or biliary disorders (including cholestasis or gallstones), or systemic lupus erythematosus.
  • History or current diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis), moderate or severe hepatic insufficiency, hemolytic uremic syndrome, headache with focal neurological symptoms, epilepsy, asthma requiring chronic oral use, multiple sclerosis, chorea minor, tetany, endometriosis, mastopathy, current premenstrual dysphoric disorder, sickle cell anemia, pancreatitis, diabetic vascular complications, or major depressive disorder.
  • Significant psychiatric condition or suicide risk, in the opinion of the investigator.
  • to any component of the product.
  • History of alcohol and/or drug abuse.
  • within the previous 5 years, except non-melanoma skin cancer, or any history of hormone-dependent malignancy or current suspicion of malignancy, including meningioma and hepatic tumors.
  • Organ transplantation within the previous 5 years or chronic disease with anticipated transplantation.
  • Use within the previous 90 days of medications known to interfere with cytochrome P450-mediated hepatic metabolism, including carbamazepine, phenytoin, primidone, oxcarbazepine, topiramate, rifampicin, ritonavir, or St. John's wort-containing products.
  • Use within the previous 90 days of direct-acting antiviral medications containing ombitasvir, paritaprevir, dasabuvir, or combinations of these agents.
  • Undiagnosed vaginal bleeding.
  • Abnormal breast examination findings or other clinically significant gynecological findings that, in the investigator's opinion, could worsen with oral use.
  • Participant living with infection or with a history of unresolved or infection.
  • Participation in another clinical trial within the previous 12 months, unless the investigator considers that direct benefit to the participant may be expected.
  • Any other clinical condition or laboratory abnormality that, in the investigator's opinion, makes the participant unsuitable for study participation.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,600 participants (estimated)

Study arms

  • Experimental
    N0999

    Drug: Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg

Interventions

  • DrugCyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg

    Drug page: Cyproterone Acetate

    Cyproterone acetate 2 mg and ethinyl estradiol 0.02 mg film-coated tablets administered in a 24+4 regimen. Each treatment pack contains one 28-tablet calendar blister composed of 24 active pink film-coated tablets and 4 inactive white film-coated tablets. Participants will receive treatment for 13 consecutive 28-day cycles.

06

What researchers measure

Primary outcomes

  1. Contraceptive Efficacy Assessed by Pearl Index in Participants Aged ≤35 Years

    Contraceptive efficacy of cyproterone acetate 2 mg plus ethinyl estradiol 0.02 mg will be evaluated using the Pearl Index in the subgroup of participants aged 35 years or younger in the intention-to-treat population with evaluable cycles. The primary analysis aims to demonstrate a 95% confidence interval upper limit of less than 5.0 pregnancies per 100 woman-years.

    Time frame: 52 weeks (12 months), corresponding to 13 consecutive 28-day treatment cycles

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2027; primary completion for May 2029, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartEst.
May 31, 2027
Primary completionEst.
May 31, 2029
CompletionEst.
May 31, 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Brazil
Show site
  • Eurofarma Laboratórios S.A · Itapevi, Brazil
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site added — first site in Brazil
    Show site
    • Eurofarma Laboratórios S.A · Itapevi, Brazil
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07714616
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
May 31, 2027 (estimated)
Primary completion
May 31, 2029 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Oct 23, 2026

Study contacts

Natalia Silva Di Gianni
Contact
natalia.gianni@eurofarma.com
+55 11 5090 8411
Taís Mendonça dos Santos
Contact
tais.santos@eurofarma.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyproterone Acetate

Start the discussion